To assess serum FABP4 and other metabolic-related parameters in Systemic Lupus Erythematosus (SLE) active and non-active episode.
Methods
Fifty-four SLE patients in Hasan Sadikin General Hospital, Bandung, Indonesia in 2018–2019 were recruited and serum samples were collected in their active and non-active episode status. Serum was analyzed for FABP4, leptin, glucose, and triglycerides. The clinical characteristics were analyzed from medical records. Disease activity was assessed with the SLEDAI-2K (≥4 defined as an active; <4 as non-active episode).
Results
Significantly correlation of Systolic Blood Pressure (SBP) (p = 0.001, r = 0.59) and C3 (p = 0.04, r = 0.47) between active and non-active episode. In non-active episode, there was significant correlation of FABP4 with Diastolic Blood Pressure (DBP) (p = 0.04, r = 0.26) and blood glucose (p = 0.01, r = −0.39). In active episode, there was significant correlation FABP4 with SBP (p = 0.04, r = −0.28) and triglyceride (p = 0.002, r = 0.55).
Conclusion
FABP4 correlates with high DBP in the non-active and high triglyceride serum in the active episode.
StojanGPetriM.Epidemiology of systemic lupus erythematosus: an update. Curr Opin Rheumatol2018;
30: 144–150.
2.
CarterEEBarrSGClarkeAE.The global burden of SLE: prevalence, health disparities and socioeconomic impact. Nat Rev Rheumatol2016;
12: 605–620.
3.
HamijoyoLCandrianitaSRahmadiAR, et al.
The clinical characteristics of systemic lupus erythematosus patients in Indonesia: a cohort registry from an Indonesia-based tertiary referral hospital. Lupus2019;
28: 1604–1606.
4.
LiuYKaplanMJ.Cardiovascular disease in systemic lupus erythematosus: an update. Curr Opin Rheumatol2018;
30: 441–448.
5.
MobiniMNiksolatFMohammadpourRADashti DargahlooSMarzbanD.Metabolic syndrome in patients with systemic lupus erythematosus: association with disease activity, disease damage and age. Int J Rheum Dis2018;
21: 1023–1030.
6.
Amaya-AmayaJMontoya-SánchezLRojas-VillarragaA.Cardiovascular involvement in autoimmune diseases. BioMed Res Int2014;
2014: 1–31.
7.
TektonidouMGWangZWardMM.Brief report: trends in hospitalizations due to acute coronary syndromes and stroke in patients with systemic lupus erythematosus, 1996 to 2012. Arthritis Rheumatol 2016;
68: 2680–2685.
ChouguleDNadkarMVenkataramanK, et al.
Adipokine interactions promote the pathogenesis of systemic lupus erythematosus. Cytokine2018;
111: 20–27.
10.
McMahonMSkaggsBJSahakianL, et al.
High plasma leptin levels confer increased risk of atherosclerosis in women with systemic lupus erythematosus, and are associated with inflammatory oxidised lipids. Ann Rheum Dis2011;
70: 1619–1624.
11.
MokCC.Metabolic syndrome and systemic lupus erythematosus: the connection. Expert Rev Clin Immunol2019;
15: 765–775.
12.
FuruhashiMSaitohSShimamotoKMiuraT.Fatty acid-binding protein 4 (FABP4): pathophysiological insights and potent clinical biomarker of metabolic and cardiovascular diseases. Clin Med Insights Cardiol2014;
8: 23–33.
13.
MiedemaMDMaziarzMBiggsML, et al.
Plasma-free fatty acids, fatty acid–binding protein 4, and mortality in older adults (from the cardiovascular health study). Am J Cardiol2014;
114: 843–848.
14.
DjousséLKhawajaOBartzTM, et al.
Plasma fatty acid–binding protein 4, nonesterified fatty acids, and incident diabetes in older adults. Diabetes Care2012;
35: 1701–1707.
15.
PeetersWde KleijnDPVinkA, et al.
Adipocyte fatty acid binding protein in atherosclerotic plaques is associated with local vulnerability and is predictive for the occurrence of adverse cardiovascular events. Eur Heart J2011;
32: 1758–1768.
16.
ParraSCabreAMarimonF, et al.
Circulating FABP4 is a marker of metabolic and cardiovascular risk in SLE patients. Lupus2014;
23: 245–254.
17.
HochbergMC.Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1997;
40: 1725.
OtsaKTalliSHardingP, et al.
Prevalence and incidence of systemic lupus erythematosus in the adult population of Estonia. Lupus2017;
26: 1115–1120.
20.
IngvarssonRBengtssonAJönsenA.Variations in the epidemiology of systemic lupus erythematosus in Southern Sweden. Lupus2016;
25: 772–780.
21.
FurstDClarkeAFernandesABancroftTGrethWIorgaS.Incidence and prevalence of adult systemic lupus erythematosus in a large US managed-care population. Lupus2013;
22: 99–105.
22.
LanataCMNitithamJTaylorKE, et al.
Genetic contributions to lupus nephritis in a multi-ethnic cohort of systemic lupus erythematous patients. PloS One2018;
13: e0199003.
23.
RizkAGheitaTANassefSAbdallahA.The impact of obesity in systemic lupus erythematosus on disease parameters, quality of life, functional capacity and the risk of atherosclerosis. Int J Rheum Dis2012;
15: 261–267.
24.
ChaiamnuaySBertoliAMRosemanJM, et al.
African–American and Hispanic ethnicities, renal involvement and obesity predispose to hypertension in systemic lupus erythematosus: results from LUMINA, a multiethnic cohort (LUMINAXLV). Ann Rheum Dis2007;
66: 618–622.
25.
TehPZakharyBSandhuVK.The impact of obesity on SLE disease activity: findings from the Southern California Lupus Registry (SCOLR). Clin Rheumatol2019;
38: 597–600.
26.
KatzPJulianLTonnerMC, et al.
Physical activity, obesity, and cognitive impairment among women with systemic lupus erythematosus. Arthritis Care Res2012;
64: 502–510.
27.
SzabóMZSzodorayPKissE.Dyslipidemia in systemic lupus erythematosus. Immunol Res2017;
65: 543–550.
CojocaruMCojocaruIMSilosiIVrabieCD.Manifestations of systemic lupus erythematosus. Maedica2011;
6: 330–336.
30.
Sola-RodríguezSGavilán-CarreraBVargas-HitosJASabioJMMorillas-de-LagunoPSoriano-MaldonadoA.Physical fitness and body composition in women with systemic lupus erythematosus. Medicina2019;
55: 57.
31.
LandechoMFTueroCValentíVBilbaoIde la HigueraMFrühbeckG.Relevance of leptin and other adipokines in obesity-associated cardiovascular risk. Nutrients2019;
11: 2664.
32.
IshimuraSFuruhashiMWatanabeY, et al.
Circulating levels of fatty acid-binding protein family and metabolic phenotype in the general population. PLoS One2013;
8: e81318.
33.
EnginA.Diet-Induced obesity and the mechanism of leptin resistance. Adv Exp Med Biol2017;
960: 381–397.
34.
Pérez-PérezAVilariño-GarcíaTFernández-RiejosPMartín-GonzálezJSegura-EgeaJJSánchez-MargaletV.Role of leptin as a link between metabolism and the immune system. Cytokine Growth Factor Rev2017;
35: 71–84.
35.
Garcia-GonzalezAGonzalez-LopezLValera-GonzalezIC, et al.
Serum leptin levels in women with systemic lupus erythematosus. Rheumatol Int2002;
22: 138–141.
36.
Munguia-RealpozoPMendoza-PintoCBenitoCS, et al.
Systemic lupus erythematosus and hypertension. Autoimmun Rev2019;
18: 102371.
37.
UrowitzMGladmanDIbanezD, et al.; Systemic Lupus International Collaborating Clinics.
Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus. Arthritis Care Res2010;
62: 881–887.
38.
ShaharirSSMustafarRMohdRMohd SaidMSGaforHA.Persistent hypertension in lupus nephritis and the associated risk factors. Clin Rheumatol2015;
34: 93–97.
39.
OspinaFEEcheverriAZambranoD, et al.
Distinguishing infections vs flares in patients with systemic lupus erythematosus. Rheumatology2017;
56: i46–i54.
40.
LittlejohnEMarderWLewisE, et al.
The ratio of erythrocyte sedimentation rate to C-reactive protein is useful in distinguishing infection from flare in systemic lupus erythematosus patients presenting with fever. Lupus2018;
27: 1123–1129.
41.
Henriquez-CamachoCLosaJ.Biomarkers for sepsis. BioMed Res Int2014;
2014: 1–6.
42.
FiroozNAlbertDWallaceDIshimoriMBerelDWeismanM.High-sensitivity C-reactive protein and erythrocyte sedimentation rate in systemic lupus erythematosus. Lupus2011;
20: 588–597.
43.
ViláLMAlarcónGSMcGwinG, et al.
Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXIX. Elevation of erythrocyte sedimentation rate is associated with disease activity and damage accrual. J Rheumatol2005;
32: 2150–2155.
44.
RuchakornNNgamjanyapornPSuangtamaiT, et al.
Performance of cytokine models in predicting SLE activity. Arthritis Res Ther2019;
21: 287.
45.
NarayananKMarwahaVShanmuganandanKShankarS.Correlation between systemic lupus erythematosus disease activity index, C3, C4 and anti-dsDNA antibodies. Med J Armed Forces India2010;
66: 102–107.
46.
Urquizu-PadillaMBaladaEVAChaconPPérezEHVilardell-TarrésMOrdi-RosJ.Changes in lipid profile between flare and remission of patients with systemic lupus erythematosus: a prospective study. J Rheumatol2009;
36: 1639–1645.
47.
LourencoEVLiuAMatareseGLa CavaA.Leptin promotes systemic lupus erythematosus by increasing autoantibody production and inhibiting immune regulation. Proc Natl Acad Sci U S A2016;
113: 10637–10642.
48.
LeeYHSongGG.Association between circulating leptin levels and systemic lupus erythematosus: an updated meta-analysis. Lupus2018;
27: 428–435.
49.
BudoffM.Triglycerides and triglyceride-rich lipoproteins in the causal pathway of cardiovascular disease. Am J Cardiol2016;
118: 138–145.
50.
FanouriakisAKostopoulouMAlunnoA, et al.
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis2019;
78: 736–745.
